Late in the afternoon on the first Friday of April, Andrew Monticelli, an oncologist at Rocky Mountain Cancer Centers, got a phone call from Jeff Sharman, the medical director of hematology research ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s CALQUENCE ® (acalabrutinib) in combination with ...

AbbVie and Johnson & Johnson got a scare this Halloween, and it came in the form of an FDA approval for AstraZeneca’s Imbruvica rival—along with a list price that undercuts the established med. On ...

When AstraZeneca ended a late-stage trial for Calquence early after seeing promising results, the news boded well for the drug’s chances in previously treated chronic lymphocytic leukemia (CLL). Now, ...

WILMINGTON, Del.--(BUSINESS WIRE)--Updated results from the ASCEND Phase III trial showed AstraZeneca’s CALQUENCE ® (acalabrutinib) maintained a statistically significant progression-free survival ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from an interim analysis of the AMPLIFY Phase III trial showed a fixed duration of AstraZeneca’s CALQUENCE® (acalabrutinib) in ...

The ECHO trial enrolled during the pandemic, and a pre-specified analysis censoring for COVID-19-related deaths was conducted. Calquence combination regimen reduced the risk of disease progression or ...

AstraZeneca PLC AZN announced that the phase III ELEVATE-TN study on its BTK inhibitor, Calquence (acalabrutinib), has met the primary endpoint. The late-stage study evaluated Calquence in combination ...

AstraZeneca’s fast-growing BTK inhibitor Calquence is already challenging class leader Imbruvica from Johnson & Johnson/AbbVie in the treatment of chronic lymphocytic leukaemia (CLL). Now, AZ has new ...

Although survival rates were similar, patients with chronic lymphocytic leukemia treated with Calquence experienced fewer side effects than those who received Imbruvica. Treatment with Calquence ...

CALQUENCE plus venetoclax with obinutuzumab reduced the risk of disease progression or death by 58% versus standard of care in this setting CALQUENCE plus venetoclax poised to become first all-oral ...

ELEVATE-RR head-to-head trial data also presented at ASH showed patients on ibrutinib experienced a 37% higher burden of adverse events of any grade while on treatment vs. patients on CALQUENCE ...